The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Phase II EPIC trial: enfortumab vedotin in advanced pancreatic adenocarcinoma
Anup Kasi, MD, MPH, University of Kansas Cancer Center, Kansas City, KS, presents the open-label, Phase II single-arm EPIC trial (NCT05915351) evaluating enfortumab vedotin (EV) in advanced pancreatic adenocarcinoma. Nectin-4, overexpressed in pancreatic adenocarcinoma, is a target for EV, an antibody-drug conjugate delivering monomethyl auristatin E. The trial includes 28 patients with locally advanced, recurrent, or metastatic disease, previously treated. EV is administered intravenously every 28 days until disease progression or unacceptable toxicity. Primary objective: overall response rate (ORR) by RECIST 1.1. Secondary objectives: safety, duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Exploratory objectives involve Nectin-4 expression and the tumor’s mutational profile. A Simon’s two-stage Minimax design will be used for statistical analysis. Enrollment is ongoing. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
